EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Circulating 3-Hydroxy Butyrate Predicts Mortality in Patients with Chronic Heart Failure with Reduced Ejection Fraction

Kristian Hylleberg Christensen, Roni R Nielsen, Morten Schou, Ida Gustafsson, Anders Jorsal, Allan Flyvbjerg, Lise Tarnow, Hans Erik Bøtker, Caroline Kistorp, Mogens Johannsen, Niels Møller, Henrik Wiggers

ESC Heart Failure · 01.04.2024 · 11 (2) · 837-845

DOI: 10.1002/ehf2.14476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 09.01.2024. Verfasst von Kristian Hylleberg Christensen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Heart Failure, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Fonden, Hjerteforeningen, Danmarks Frie Forskningsfond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

In patients with chronic heart failure with reduced ejection fraction (HFrEF), myocardial ketone metabolism is increased and short-term treatment with the ketone body 3-hydroxy butyrate (3-OHB) has beneficial haemodynamic effects. In patients with HFrEF, we investigated whether the level of circulating 3-OHB predicted all-cause mortality and sought to identify correlations between patient characteristics and circulating 3-OHB levels. Methods and results We conducted a cohort study in 218 patients with HFrEF. Plasma 3-OHB levels were measured using high-performance liquid chromatography tandem mass spectrometry. Data on all-cause mortality were obtained by reviewing the patients’ medical records, which are linked to the national ‘Central Person Registry’ that registers the timing of all deaths in the country. Mean left ventricular ejection fraction was 35 ± 8.6%, mean age was 67 ± 10 years, 54% were New York Heart Association II, and 27% had type 2 diabetes mellitus. Median follow-up time was 7.3 (interquartile range 6.3–8.4) years. We observed large variations in 3-OHB levels between patients (median 59 μM, range: 14–694 μM). Patients with 3-OHB levels above the median displayed a markedly increased risk of death compared with those with low levels {hazard ratio [HR]: 2.1 [95% confidence interval (CI): 1.3–3.5], P = 0.003}. In a multivariate analysis, 3-OHB predicted mortality independently of known chronic heart failure risk factors [HR: 1.004 (95% CI: 1.001–1.007), P = 0.02] and with a similar statistical strength as N-terminal pro-brain natriuretic peptide (NT-proBNP) [HR: 1.0005 (95% CI: 1.000–1.001), P = 0.02]. For every 100 μmol increase in plasma 3-OHB, the hazard of death increased by 49%. The following factors significantly predicted 3-OHB levels in the univariate analysis: free fatty acids (FFAs) [β: 238 (95% CI: 185–292), P < 0.0001], age [β: 2.43 (95% CI: 1.14–3.72), P < 0.0001], plasma insulin {β: −0.28 [95% CI: −0.54–(−0.02)], P = 0.036}, body mass index {β: −3.15 [95% CI: −5.26–(−0.05)], P = 0.046}, diabetes [β: 44.49 (95% CI: 14.84–74.14), P = 0.003], glycosylated haemoglobin [β: 1.92 (95% CI: 0.24–3.59), P = 0.025], New York Heart Association class [β: 26.86 (95% CI: 5.99–47.72), P = 0.012], and NT-proBNP [β: 0.03 (95% CI: 0.01–0.04), P = 0.001]. In a multivariate analysis, only FFAs predicted 3-OHB levels [β: 216 (95% CI: 165–268), P > 0.001].

Conclusions

In patients with HFrEF, circulating 3-OHB was a strong predictor of all-cause mortality independently of NT-proBNP. Circulating FFAs were the best predictor of 3-OHB levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureDiabetes Mellitus, Type 2HumansMiddle AgedAgedStroke VolumeVentricular Function, LeftPrognosis3-Hydroxybutyric AcidCohort Studies

Stichwörter der Autor:innen

3‐Hydroxy butyrateHeart failureKetone bodiesMetabolismPrognosis

Substanzen

3-Hydroxybutyric Acid

Autor:innen und Institutionen

  • Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Cardiology, Herlev-Gentofte University Hospital, Herlev, Denmark.
  • Department of Cardiology, Bispebjerg Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Department of Internal Medicine, Regional Hospital Horsens, Horsens, Denmark.
  • Steno Diabetes Center Copenhagen, The Capital Region of Denmark and University of Copenhagen, Copenhagen, Denmark.
  • Steno Diabetes Center, Sjaelland, Denmark.

Förderung

  • Novo Nordisk Fonden
  • Hjerteforeningen
  • Danmarks Frie Forskningsfond

Zitieren

APA

Christensen, K. H., Nielsen, R. R., Schou, M., Gustafsson, I., Jorsal, A., Flyvbjerg, A., Tarnow, L., Bøtker, H. E., Kistorp, C., Johannsen, M., Møller, N., & Wiggers, H. (2024). Circulating 3-Hydroxy Butyrate Predicts Mortality in Patients with Chronic Heart Failure with Reduced Ejection Fraction. ESC Heart Failure, 11(2), 837-845. https://doi.org/10.1002/ehf2.14476

Vancouver

Christensen KH, Nielsen RR, Schou M, Gustafsson I, Jorsal A, Flyvbjerg A, et al. Circulating 3-Hydroxy Butyrate Predicts Mortality in Patients with Chronic Heart Failure with Reduced Ejection Fraction. ESC Heart Failure. 2024;11(2):837-845. doi:10.1002/ehf2.14476

BibTeX
@article{Christensen2024,
  author = {Christensen, Kristian Hylleberg and Nielsen, Roni R and Schou, Morten and Gustafsson, Ida and Jorsal, Anders and Flyvbjerg, Allan and Tarnow, Lise and Bøtker, Hans Erik and Kistorp, Caroline and Johannsen, Mogens and Møller, Niels and Wiggers, Henrik},
  title = {Circulating 3-Hydroxy Butyrate Predicts Mortality in Patients with Chronic Heart Failure with Reduced Ejection Fraction},
  journal = {ESC Heart Failure},
  year = {2024},
  volume = {11},
  number = {2},
  pages = {837--845},
  doi = {10.1002/ehf2.14476}
}
Kostenlos starten →